Genor Biopharma Holdings Ltd (6998) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Genor Biopharma Holdings Ltd HK$3.59, price HK$1.69, upside +112.9%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Genor Biopharma Holdings Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range HK$0.8800 – HK$18.80 · fair‑value band HK$2.60 – HK$4.66 · the HK$1.69 price screens below the HK$3.59 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Genor Biopharma Holdings in your weekly email
Every Wednesday you see whether Genor Biopharma Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally.
Show more
Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical trial for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are Phase I clinical trial. It also provides Vancocin for multidrug-resistant gram-positive bacteria; Ceclor for mild to moderate community-acquired bacterial infections in children; Yirui Ping for nebulized inhalation therapy; Vascepa for cardiovascular risk reduction; Mulpleta for reducing bleeding risk; Jing Zhu Da for breast cancer treatment; Recormon for CRA indication; and three siRNA candidates for chronic disease treatment, as well as entinostat and lerociclib hydrochloride tablets. In addition, the company is involved in marketing, commercialization, and trading of pharmaceutical products; research and development of respiratory products; and consultancy and promotion services. Its products are used in oncology, autoimmune, cardiovascular, respiratory, and anti-infective therapeutic areas. Edding Genor Group Holdings Limited was founded in 2001 and is headquartered in Zhuhai, China.
Stock analysis
Genor Biopharma Holdings Ltd (6998) currently trades at HK$1.69, while our model-based Fair Value estimate is HK$3.59, implying the stock looks roughly 53.0% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of HK$4.40 per share, and 21 of the 24 models we run sit above the HK$1.69 price.
Bear case: the Asset-Based group reads lowest at HK$1.30, and 3 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$2.60 (bear) to HK$4.66 (bull), the price of HK$1.69 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Genor Biopharma Holdings Ltd reported revenue of 2.7B CNY in FY2025 versus 0 CNY in FY2021. Reported net income was 433M CNY in FY2025.
Key figures
Market cap HK$3.5B (≈ $445M) · P/E ratio 6.5 · P/S ratio 1.04 · EPS (TTM) HK$−0.1000 · Dividend yield 1.3% · Net margin 16.1% · Return on equity 12.8% · Return on assets (EBIT) −13.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 61% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 113%, 6998 screens cheaper than that median.
Fair Value models
Bear HK$2.60Fair Value HK$3.59Bull HK$4.66
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.83/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−2.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+426.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+197.3%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+129.1%
’18
’19
’20
’22
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8,490.2% (2020) → 25.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−3.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about −5.8% a year for the price.
Compare Genor Biopharma Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks
Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside+100% · Top 25%
Profitability
Return on equity (TTM)13% · Above median
Return on assets7% · Top 25%
Net margin (TTM)16% · Top 25%
Operating margin (TTM)26% · Top 25%
Growth and dividend
Revenue growth15% · Above median
Dividend yield (TTM)1.3% · Below median
Balance sheet
Debt / equity0.10× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Genor Biopharma Holdings Ltd (6998) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$3.59 versus a price of HK$1.69, about +113% upside (undervalued).
What is the fair value of 6998?
Our model-based fair value for Genor Biopharma Holdings Ltd is HK$3.59 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$1.69.
What is the quality score of 6998?
Genor Biopharma Holdings Ltd has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genor Biopharma Holdings Ltd (6998)?
Our model-based price target is the fair value of HK$3.59 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario HK$2.60, optimistic scenario HK$4.66. It is a calculation from audited fundamentals, not an analyst target.
What is the Genor Biopharma Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$3.59, about +113% upside versus a price of HK$1.69 (undervalued). Cautious scenario HK$2.60, optimistic scenario HK$4.66. The calculation is refreshed regularly with new filings.
What is the revenue of Genor Biopharma Holdings Ltd (6998)?
Genor Biopharma Holdings Ltd reported trailing-twelve-month revenue of about HK$2.5B (latest available figure, as of Sep 24, 2026).
Does Genor Biopharma Holdings Ltd pay a dividend?
Genor Biopharma Holdings Ltd currently shows a dividend yield of about 1.33% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Genor Biopharma Holdings Ltd (6998)?
For today's price to be fair in a discounted-cash-flow model, Genor Biopharma Holdings Ltd would have to grow free cash flow by -3.8 % per year for five years (discount rate 11.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +197.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 6998 use?
Our models discount Genor Biopharma Holdings Ltd at 11.4 %: a base by market capitalisation (small), damped by beta 0.85, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Genor Biopharma Holdings Ltd that is -3.8 % per year a year over ten years, using the same discount rate (11.4 %) and the same formula as our fair value.
How much growth has Genor Biopharma Holdings Ltd (6998) delivered so far?
Over the past 5 years revenue at Genor Biopharma Holdings Ltd grew +197.3 % a year. The price currently implies -3.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Genor Biopharma Holdings Ltd (6998) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Genor Biopharma Holdings Ltd (-3.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Genor Biopharma Holdings Ltd (6998)?
The free-cash-flow yield on the price is 14.12 %: that much free cash flow Genor Biopharma Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Genor Biopharma Holdings Ltd (6998)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genor Biopharma Holdings Ltd it is HK$3.59 per share (as of Sep 24, 2026), against a price of HK$1.69. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Genor Biopharma Holdings Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6998 trades below its calculated fair value: price HK$1.69, fair value HK$3.59, a gap of about +113% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6998?
No. The price is what the market pays today (HK$1.69); the fair value is what the company's own numbers justify (HK$3.59). For Genor Biopharma Holdings Ltd the two are HK$1.90 per share apart. That gap is exactly why we show both numbers side by side.
How much is Genor Biopharma Holdings Ltd worth?
The market values Genor Biopharma Holdings Ltd at about HK$3.5B (market capitalisation, as of Sep 24, 2026). Per share that is HK$1.69; our models calculate a fair value of HK$3.59 per share.
What do the bullish and bearish scenarios say about 6998?
Our models span a range for Genor Biopharma Holdings Ltd: cautious scenario HK$2.60, base HK$3.59, optimistic HK$4.66 per share (as of Sep 24, 2026, price HK$1.69). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6998?
Genor Biopharma Holdings Ltd trades at a price-to-earnings ratio of 6.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$3.59 is built from several models across several years. Other multiples: P/B 0.9, P/S 1.4, EV/EBITDA 3.3.
How solid is the balance sheet of Genor Biopharma Holdings Ltd (6998)?
Balance-sheet figures for Genor Biopharma Holdings Ltd (as of Sep 24, 2026): return on equity 12.8%, debt of 0.10 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 6998 from its 52-week high?
Genor Biopharma Holdings Ltd trades at HK$1.69, about 61% below its 52-week high of HK$4.27 and 15% above the low of HK$1.47 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of HK$3.59 is for.
Which stocks are comparable to Genor Biopharma Holdings Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genor Biopharma Holdings Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price HK$1.69, calculated fair value HK$3.59 (+113%), Quality Score 40/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6998 calculated?
We run Genor Biopharma Holdings Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$3.59, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Genor Biopharma Holdings Ltd currently trades 113 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genor Biopharma Holdings Ltd (6998)?
The closing price on Sep 24, 2026 was HK$1.69. Our model-based fair value is HK$3.59, about +113% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genor Biopharma Holdings Ltd right now?
The large discount to fair value meets weak quality (40/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (HK$2.60). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Genor Biopharma Holdings Ltd
How large is the market capitalisation of Genor Biopharma Holdings Ltd (6998)?
The market capitalisation of Genor Biopharma Holdings Ltd is HK$3.5B (≈ $445M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genor Biopharma Holdings Ltd (6998)?
The price-to-sales ratio of Genor Biopharma Holdings Ltd is 1.04 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genor Biopharma Holdings Ltd (6998)?
Earnings per share at Genor Biopharma Holdings Ltd are HK$−0.1000 (price ÷ EPS = P/E 6.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Genor Biopharma Holdings Ltd (6998)?
The dividend yield of Genor Biopharma Holdings Ltd is 1.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Genor Biopharma Holdings Ltd (6998)?
The net margin of Genor Biopharma Holdings Ltd is 16.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genor Biopharma Holdings Ltd (6998)?
The return on equity (ROE) of Genor Biopharma Holdings Ltd is 12.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genor Biopharma Holdings Ltd (6998)?
On an EBIT basis the return on assets of Genor Biopharma Holdings Ltd is −13.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genor Biopharma Holdings Ltd (6998)?
The operating margin of Genor Biopharma Holdings Ltd is 26.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genor Biopharma Holdings Ltd (6998)?
Revenue at Genor Biopharma Holdings Ltd is growing +15.3% versus a year earlier (3y avg +426%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Genor Biopharma Holdings Ltd (6998)?
Earnings per share at Genor Biopharma Holdings Ltd are growing +104% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Genor Biopharma Holdings Ltd (6998) carry?
The net debt of Genor Biopharma Holdings Ltd is HK$431M (fiscal year 2025, ≈ 1.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Genor Biopharma Holdings Ltd in the live analysis
One click puts Genor Biopharma Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
